Conditional

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
목요일, 3월 7, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Key Points: 
  • SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Retrieved on: 
목요일, 2월 22, 2024

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024 at 1:05 p.m.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024 at 1:05 p.m.
  • ET (10:05 a.m. PT).
  • A live audio webcast of the fireside chat will be available here and will be available for replay for 90 days following the presentation.

Housing Works Upholds Promise to New Yorkers with Launch of CAURD Community Initiative

Retrieved on: 
목요일, 2월 29, 2024

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Housing Works made history when it opened New York State's first licensed adult-use dispensary, Housing Works Cannabis Co (HWCC), in 2022. With that singular experience as the frontrunner in the state's CAURD (Conditional Adult-Use Retail Dispensary) licensing program, Housing Works has created and launched its CAURD Community initiative, a new retail business support network for licensed cannabis entrepreneurs.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Housing Works made history when it opened New York State's first licensed adult-use dispensary, Housing Works Cannabis Co (HWCC), in 2022.
  • With that singular experience as the frontrunner in the state's CAURD (Conditional Adult-Use Retail Dispensary) licensing program, Housing Works has created and launched its CAURD Community initiative, a new retail business support network for licensed cannabis entrepreneurs.
  • Housing Works has served as a leader in the social enterprise space in the United States since its founding in 1990.
  • To learn more about Housing Works' CAURD Community initiative, please visit hwcannabis.co/community/ .

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
목요일, 2월 15, 2024

Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.

Key Points: 
  • Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $59.7 million, compared to $58.1 million for the same period in 2022.
  • Total other income, net, for the fourth quarter of 2023 was $5.7 million, compared to $1.1 million for the same period in 2022.
  • ET to discuss company updates as well as fourth quarter and full year 2023 financial results.

Huge Launches Culture Decoder, a Comprehensive Tool for Analyzing Cultural Data

Retrieved on: 
월요일, 2월 5, 2024

By analyzing billions of data points, the proprietary tool assesses trend relevance for target customer groups; calculates the size, sentiment, and momentum of each trend; and provides actionable and data-driven recommendations to help brands drive engagement.

Key Points: 
  • By analyzing billions of data points, the proprietary tool assesses trend relevance for target customer groups; calculates the size, sentiment, and momentum of each trend; and provides actionable and data-driven recommendations to help brands drive engagement.
  • The tool also provides users with the context and reasons trends matter within an industry, as well as the relationship seen between them.
  • “But too often they use the same list of banal customer data categories to get equally banal business results.
  • Culture Decoder can offer them the fully comprehensive insights they need to make more timely, informed decisions that drive loyalty and growth.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
일요일, 2월 4, 2024

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

STEMCELL Technologies Announces Acquisition of Propagenix Inc.

Retrieved on: 
금요일, 1월 19, 2024

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.

Key Points: 
  • STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
  • View the full release here: https://www.businesswire.com/news/home/20240119648511/en/
    STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
  • (Pictured: STEMCELL's headquarters in Vancouver, BC) (Photo: Business Wire)
    “The acquisition of Propagenix is an important step in STEMCELL’s growth journey and an achievement for Canada's biotechnology industry,” said Dr. Allen Eaves, President and CEO, STEMCELL.
  • “We are delighted that the amazing team of scientists at STEMCELL will ensure Propagenix technologies and capabilities for epithelial cell biology are deployed to their fullest to serve the life science research community,” said Dr. Brian Pollok on behalf of Propagenix co-founders.

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Retrieved on: 
월요일, 1월 8, 2024

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million. For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million. The Company ended 2023 with approximately $567 million in cash, cash equivalents, and marketable securities which is expected to support operations into 2028. The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipated milestones for 2024.

Key Points: 
  • For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million.
  • The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipated milestones for 2024.
  • "Our strong fourth quarter results reflect the growing demand for FILSPARI in IgAN driven by our field teams’ education and outreach efforts to healthcare providers,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
  • The Company expects to announce complete full year 2023 financial results and provide a corporate update in February.

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

Retrieved on: 
수요일, 1월 3, 2024

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
  • He succeeds Si-ping Han, Ph.D., co-founder of Switch Therapeutics, who will transition to an advisory role and serve on Switch’s Scientific Advisory Board.
  • “Charles joins our leadership team with extensive expertise in oligonucleotide chemistry and RNA-based therapeutics, and we are delighted to welcome him to Switch.
  • He will play a crucial role as we continue driving our novel CASi platform forward for the treatment of central nervous system (CNS) diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
수요일, 12월 20, 2023

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024.

Key Points: 
  • SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024.